SG10201600912SA - Vectors conditionally expressing protein - Google Patents
Vectors conditionally expressing proteinInfo
- Publication number
- SG10201600912SA SG10201600912SA SG10201600912SA SG10201600912SA SG10201600912SA SG 10201600912S A SG10201600912S A SG 10201600912SA SG 10201600912S A SG10201600912S A SG 10201600912SA SG 10201600912S A SG10201600912S A SG 10201600912SA SG 10201600912S A SG10201600912S A SG 10201600912SA
- Authority
- SG
- Singapore
- Prior art keywords
- expressing protein
- conditionally expressing
- vectors
- vectors conditionally
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
- C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/75—Vector systems having a special element relevant for transcription from invertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161449536P | 2011-03-04 | 2011-03-04 | |
US201161478881P | 2011-04-25 | 2011-04-25 | |
US201161490535P | 2011-05-26 | 2011-05-26 | |
US201161562342P | 2011-11-21 | 2011-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201600912SA true SG10201600912SA (en) | 2016-03-30 |
Family
ID=46798719
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201600912SA SG10201600912SA (en) | 2011-03-04 | 2012-03-02 | Vectors conditionally expressing protein |
SG2013063045A SG192856A1 (en) | 2011-03-04 | 2012-03-02 | Vectors conditionally expressing protein |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013063045A SG192856A1 (en) | 2011-03-04 | 2012-03-02 | Vectors conditionally expressing protein |
Country Status (9)
Country | Link |
---|---|
US (3) | US9402919B2 (fr) |
EP (2) | EP2681327B1 (fr) |
JP (3) | JP6189754B2 (fr) |
CN (1) | CN103534355A (fr) |
AU (1) | AU2012225749B2 (fr) |
CA (1) | CA2828411A1 (fr) |
SG (2) | SG10201600912SA (fr) |
TW (1) | TWI582108B (fr) |
WO (1) | WO2012122025A2 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013158871A1 (fr) * | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilisation de l'érythropoïétine et de dérivés pour le traitement de l'hypertension |
JP6646282B2 (ja) * | 2014-04-24 | 2020-02-14 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 多発性硬化症のためのaav系遺伝子療法 |
EP4112071A1 (fr) * | 2014-08-26 | 2023-01-04 | HSF Pharmaceuticals | Nouveaux agents d'immunisation et procédés d'utilisation associés |
JP6383621B2 (ja) * | 2014-09-24 | 2018-08-29 | 太陽インキ製造株式会社 | 硬化性組成物、ドライフィルム、硬化物、プリント配線板およびプリント配線板の製造方法 |
AU2016267687B2 (en) * | 2015-05-28 | 2022-04-07 | Cornell University | Adeno-associated virus mediated delivery of C1EI as a therapy for angioedema |
EP3302540A4 (fr) * | 2015-05-28 | 2018-08-22 | Cornell University | Administration à médiation par un virus adéno-associé de c1ei en tant que traitement contre l'angio- dème |
AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
WO2017083750A1 (fr) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
EP3235516B1 (fr) * | 2016-04-22 | 2019-06-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | Vecteur de virus adéno-associés (aav) régulable |
JP2019519225A (ja) * | 2016-05-25 | 2019-07-11 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 活性依存性発現構築物およびこれを使用する方法 |
CA3025667A1 (fr) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Recepteurs antigeniques chimeriques specifiques de cd33 |
UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
NZ752941A (en) * | 2016-11-09 | 2023-04-28 | Intrexon Corp | Frataxin expression constructs |
EP4382913A2 (fr) | 2017-01-10 | 2024-06-12 | Precigen, Inc. | Modulation de l'expression de polypeptides par l'intermédiaire de nouveaux systèmes d'expression de commutateurs géniques |
EP3635132A4 (fr) | 2017-06-07 | 2021-05-26 | Intrexon Corporation | Expression de nouvelles étiquettes de cellules |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
US11306329B2 (en) | 2018-02-19 | 2022-04-19 | City Of Hope | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
AU2019231652A1 (en) | 2018-03-06 | 2020-10-01 | Precigen, Inc. | Hepatitis B vaccines and uses of the same |
CA3103372A1 (fr) * | 2018-06-27 | 2020-01-02 | Precigen, Inc. | Polytherapie regulee in vivo pour le traitement du cancer |
EP3820484A4 (fr) * | 2018-07-10 | 2022-05-04 | Precigen, Inc. | Récepteurs antigéniques chimériques specifiques de ror-1 et utilisations associées |
EP3935077A1 (fr) | 2019-03-08 | 2022-01-12 | Obsidian Therapeutics, Inc. | Compositions de cd40l et procédés de régulation accordable |
WO2020206056A1 (fr) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides et procédés de protection de plantes |
JP2023509770A (ja) | 2020-01-08 | 2023-03-09 | オブシディアン セラピューティクス, インコーポレイテッド | 転写の調節可能な制御のための組成物及び方法 |
TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
WO2021211640A1 (fr) * | 2020-04-14 | 2021-10-21 | University Of Florida Research Foundation, Incorporated | Effets améliorés d'immunothérapie génique et d'immunosuppresseurs lors d'une sclérose en plaques |
CN112741895A (zh) * | 2021-01-19 | 2021-05-04 | 中国人民解放军陆军军医大学 | Epo类似物在制备治疗脓毒症药物中的应用 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3360004A (en) | 1965-09-07 | 1967-12-26 | Bendix Corp | Pressure proportioning valve |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
FR2593630B1 (fr) | 1986-01-27 | 1988-03-18 | Maurice Francois | Ecran d'affichage a matrice active a resistance de drain et procedes de fabrication de cet ecran |
US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
CA2043775A1 (fr) | 1990-06-14 | 1991-12-15 | Dat P. Le | Dibenzoylalkylcyanohydrazines |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
US20020107211A1 (en) * | 1995-06-07 | 2002-08-08 | The Rockefeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5962311A (en) | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
EP0813604B1 (fr) | 1995-03-03 | 2005-04-20 | Syngenta Participations AG | Regulation de l'expression genique dans les plantes par transactivation induite par recepteur en presence d'un ligand chimique |
RU97121687A (ru) | 1995-05-26 | 2005-01-20 | Синджента Лимитед (Gb) | Ген-переключатель, представляющий ген рецептора экдизона |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
IL122614A0 (en) | 1995-06-15 | 1998-08-16 | Introgene Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
WO1998007878A2 (fr) * | 1996-08-23 | 1998-02-26 | Arch Development Corporation | Expression prolongee de produits genetiques par transformation de cellules musculaires |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
DE69820450T2 (de) | 1997-06-09 | 2004-05-27 | Genvec, Inc. | Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten |
US20100190692A1 (en) | 1997-07-04 | 2010-07-29 | Van Groeninghen Johannes C | Methods for reducing gnrh-positive tumor cell proliferation |
AU3659497A (en) * | 1997-07-11 | 1999-02-08 | Canji, Inc. | Organ-specific targeting of cationic amphiphile/retinobl astoma encoding dna complexes for gene therapy |
AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
US20020048792A1 (en) | 1997-08-26 | 2002-04-25 | Ariad Gene Therapeutics, Inc. | Methods and materials for regulated production of proteins |
JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、dna結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
US6479653B1 (en) | 1997-08-26 | 2002-11-12 | Ariad Gene Therapeutics, Inc. | Compositions and method for regulation of transcription |
AU749856B2 (en) | 1997-09-23 | 2002-07-04 | Genvec, Inc. | Plasmids for construction of eukaryotic viral vectors |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
WO1999054441A1 (fr) | 1998-04-22 | 1999-10-28 | Genvec, Inc. | Purification efficace d'adenovirus |
US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
US6258603B1 (en) | 1998-06-17 | 2001-07-10 | Rohm And Haas Company | Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
DE19831420A1 (de) * | 1998-07-14 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren |
US5965358A (en) | 1998-08-26 | 1999-10-12 | Genvec, Inc. | Method for assessing the relative purity of viral gene transfer vector stocks |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
US6831060B2 (en) * | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
ATE252601T1 (de) * | 1999-05-17 | 2003-11-15 | Conjuchem Inc | Lang wirkende insulinotrope peptide |
US6225895B1 (en) | 1999-05-26 | 2001-05-01 | Floyd E. Bigelow, Jr. | Towed vehicle monitor system |
AU6953100A (en) | 1999-07-09 | 2001-01-30 | Mayo Foundation For Medical Education And Research | Cftr polypeptides, fragments thereof and methods of use to overcome biosyntheticmisprocessing |
US20030186386A1 (en) * | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
EP1266015B1 (fr) | 2000-03-22 | 2006-08-30 | RheoGene Holdings Inc. | Nouveau systeme d'expression genetique inducible fonde sur le le recepteur a l'ecdysone |
US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
EP1456346B1 (fr) | 2001-02-20 | 2012-02-15 | Intrexon Corporation | Nouveau systeme d'expression genetique inductible base sur le recepteur d'ecdysone/recepteur de retinoide x invertebre |
EP1572862B1 (fr) | 2001-02-20 | 2012-08-01 | Intrexon Corporation | Recepteurs x de retinoides chimeriques et utilisations de ceux-ci dans un nouveau systeme d'expression de gene inductible fonde sur un recepteur d'ecdysone |
JP4328094B2 (ja) | 2001-02-20 | 2009-09-09 | イントレクソン・コーポレイション | 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用 |
EP1534738B1 (fr) | 2001-02-20 | 2012-06-20 | Intrexon Corporation | Nouveaux recepteurs a mutant de substitution et utilisation de ceux-ci dans un systeme d'expression de gene inductible fonde sur un recepteur nucleaire |
EP1372678A2 (fr) * | 2001-03-09 | 2004-01-02 | Board of Regents, The University of Texas System | Vecteurs, compositions et procedes de traitement de trouble vasculaire |
WO2002072019A2 (fr) | 2001-03-13 | 2002-09-19 | Vical Incorporated | Therapie par polynucleotide codant un interferon-beta pour des maladies auto-immunes et inflammatoires |
US7588758B2 (en) * | 2001-09-11 | 2009-09-15 | University Of Medicine And Dentistry Of New Jersey | COX-2 function and wound healing |
CA2820170C (fr) | 2001-09-26 | 2016-07-05 | Intrexon Corporation | Acides nucleiques, polypeptides du recepteur de l'ecdysone des aleyrodidae et utilisations ces derniers |
CA2820144C (fr) | 2001-09-26 | 2017-06-20 | Intrexon Corporation | Acides nucleiques du recepteur a l'ecdysone de la cicadelle, polypeptides, et utilisation de ceux-ci |
US20030176328A1 (en) | 2001-12-21 | 2003-09-18 | Maxygen Aps | Adiponectin fragments and conjugates |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US20050228016A1 (en) | 2002-06-13 | 2005-10-13 | Enrique Michelotti | Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US20040049437A1 (en) | 2002-09-11 | 2004-03-11 | Govone Solutions, Lp | Method, system and computer program product for automating transaction tax calculation |
AU2003300781A1 (en) | 2002-09-25 | 2004-05-04 | The Center For Blood Research, Inc. | Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
US20080050808A1 (en) | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
US7785871B2 (en) | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
US6989369B2 (en) | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
ES2447423T3 (es) | 2003-08-29 | 2014-03-12 | Dyax Corp. | Inhibidores de proteasa poli-pegilados |
WO2005026457A1 (fr) | 2003-09-15 | 2005-03-24 | Jeong Ho Yang | Unite de douche amovible de type a fixation |
AU2004288831B2 (en) | 2003-11-12 | 2010-08-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
US20050145385A1 (en) | 2004-01-05 | 2005-07-07 | Nguyen Philip D. | Methods of well stimulation and completion |
US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
ES2603062T3 (es) | 2004-05-18 | 2017-02-23 | Intrexon Corporation | Métodos de ensamblaje dinámico de vectores para la clonación de ADN de vectores plasmídicos |
EP1778220A1 (fr) | 2004-07-12 | 2007-05-02 | Phenomix Corporation | Composes cyano contraints |
US20060027071A1 (en) | 2004-08-06 | 2006-02-09 | Barnett Ronald J | Tensegrity musical structures |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US8067365B2 (en) | 2004-11-22 | 2011-11-29 | University Of Utah Research Foundation | Erythropoietin for treatment of multi-organ failure |
CN101084227B (zh) | 2004-12-20 | 2011-11-16 | 惠氏公司 | 雷帕霉素类似物及其治疗神经紊乱、增殖性和炎性疾病的用途 |
WO2006068905A2 (fr) | 2004-12-20 | 2006-06-29 | Wyeth | Derives de paramycine et leurs utilisations dans le traitement de troubles neurologiques |
US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
MX2007011453A (es) | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Inhibidores de la dipeptidil peptidasa-iv. |
JP2008546732A (ja) | 2005-06-23 | 2008-12-25 | アプラゲン ゲーエムベーハー | 多価化合物 |
WO2007074747A1 (fr) | 2005-12-26 | 2007-07-05 | Kuraray Co., Ltd. | Materiau pour une culture de cellule |
WO2007106746A2 (fr) | 2006-03-10 | 2007-09-20 | Dyax Corp. | Formulations d'écallantide |
EP2032600A2 (fr) * | 2006-05-19 | 2009-03-11 | Glycofi, Inc. | Compositions d'érythropoïétine |
CN105820231A (zh) * | 2006-08-04 | 2016-08-03 | 普罗龙药品有限责任公司 | 修饰型促红细胞生成素 |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
CA2676036A1 (fr) | 2007-02-02 | 2008-08-14 | Amgen Inc. | Hepcidine, antagonistes de l'hepcidine, et procedes d'utilisation |
EP1972349A1 (fr) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation |
TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽b2受體調節劑 |
ES2672513T3 (es) | 2007-05-29 | 2018-06-14 | Intrexon Corporation | Ligandos de diacilhidrazina quirales para modular la expresión genética exógena a través del complejo del receptor de ecdisona |
WO2009010107A1 (fr) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Utilisation d'activation ou de stimulation du récepteur de l'epo pour l'amélioration du score edss dans des patients présentant une sclérose en plaques |
CN101835908A (zh) | 2007-08-23 | 2010-09-15 | 英特瑞克斯顿股份有限公司 | 诊断疾病的方法和组合物 |
AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
WO2009045370A2 (fr) | 2007-09-28 | 2009-04-09 | Intrexon Corporation | Constructions et bioréacteurs de commutation de gène théapeutique destinés à l'expression de molécules biothérapeutiques, et utilisation de ceux-ci |
HUE024479T2 (en) * | 2007-10-08 | 2016-01-28 | Intrexon Corp | Genetically altered dendritic cells and uses for cancer treatment |
US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
EP2296632A4 (fr) | 2008-07-14 | 2014-11-12 | Otonomy Inc | Compositions et procédés modulant l apoptose à libération contrôlée pour le traitement de troubles otiques |
EP2342223B1 (fr) | 2008-09-26 | 2017-04-26 | Ambrx, Inc. | Polypeptides d érythropoïétine animale modifiés et leurs utilisations |
WO2010042189A2 (fr) * | 2008-10-08 | 2010-04-15 | Intrexon Corporation | Cellules modifiées exprimant des immuno-modulateurs multiples et leurs utilisations |
CA3019967A1 (fr) | 2008-11-13 | 2010-05-20 | The General Hospital Corporation | Procedes et compositions pour la regulation de l'homeostasie du fer par modulation de la proteine bmp-6 |
CA2745329C (fr) * | 2008-12-04 | 2022-07-12 | Opko Curna, Llc | Traitement de maladies liees a l'erythropoietine (epo) par inhibition d'un transcrit antisens naturel de l'epo |
WO2010129310A1 (fr) | 2009-04-27 | 2010-11-11 | Roswell Park Cancer Institute | Réactifs et procédés de production de peptides sécrétés bioactifs |
KR20180108886A (ko) | 2010-03-23 | 2018-10-04 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터,상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
EP2808057B1 (fr) | 2013-05-31 | 2016-02-03 | RaySearch Laboratories AB | Procédé et système de planification de traitement radiothérapeutique robuste |
-
2012
- 2012-03-02 SG SG10201600912SA patent/SG10201600912SA/en unknown
- 2012-03-02 EP EP12755403.8A patent/EP2681327B1/fr not_active Not-in-force
- 2012-03-02 EP EP18188076.6A patent/EP3450568A3/fr not_active Withdrawn
- 2012-03-02 CA CA2828411A patent/CA2828411A1/fr not_active Abandoned
- 2012-03-02 US US14/001,943 patent/US9402919B2/en active Active
- 2012-03-02 JP JP2013556905A patent/JP6189754B2/ja not_active Expired - Fee Related
- 2012-03-02 SG SG2013063045A patent/SG192856A1/en unknown
- 2012-03-02 AU AU2012225749A patent/AU2012225749B2/en not_active Ceased
- 2012-03-02 CN CN201280021577.XA patent/CN103534355A/zh active Pending
- 2012-03-02 WO PCT/US2012/027515 patent/WO2012122025A2/fr active Application Filing
- 2012-03-03 TW TW101107160A patent/TWI582108B/zh not_active IP Right Cessation
-
2016
- 2016-05-11 US US15/151,947 patent/US20160317678A1/en not_active Abandoned
-
2017
- 2017-03-08 JP JP2017044305A patent/JP2017141245A/ja not_active Withdrawn
- 2017-06-27 JP JP2017125428A patent/JP2017212995A/ja not_active Withdrawn
-
2018
- 2018-05-31 US US15/993,773 patent/US20180344876A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2012225749A1 (en) | 2013-03-14 |
JP2017141245A (ja) | 2017-08-17 |
AU2012225749B2 (en) | 2015-01-22 |
EP2681327A4 (fr) | 2015-06-03 |
TWI582108B (zh) | 2017-05-11 |
CN103534355A (zh) | 2014-01-22 |
EP3450568A3 (fr) | 2019-04-24 |
SG192856A1 (en) | 2013-09-30 |
JP2014512808A (ja) | 2014-05-29 |
WO2012122025A2 (fr) | 2012-09-13 |
US20160317678A1 (en) | 2016-11-03 |
EP2681327B1 (fr) | 2018-11-21 |
US20180344876A1 (en) | 2018-12-06 |
JP2017212995A (ja) | 2017-12-07 |
EP2681327A2 (fr) | 2014-01-08 |
US20140308247A1 (en) | 2014-10-16 |
US9402919B2 (en) | 2016-08-02 |
CA2828411A1 (fr) | 2012-09-13 |
TW201309726A (zh) | 2013-03-01 |
JP6189754B2 (ja) | 2017-08-30 |
WO2012122025A3 (fr) | 2013-04-25 |
EP3450568A2 (fr) | 2019-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201600912SA (en) | Vectors conditionally expressing protein | |
IL230918A0 (en) | Modified proteins and peptides | |
GB201108879D0 (en) | Vector | |
EP2588129A4 (fr) | Dégradation des protéines ciblées par de petites molécules | |
ZA201308824B (en) | Light-sensetive chimeric gpcr protein | |
EP2749647A4 (fr) | Adénovirus apte à se répliquer conditionnellement | |
EP2698386A4 (fr) | Protéine de fusion | |
EP2683742A4 (fr) | Protéines hybrides npp1 | |
GB201111183D0 (en) | Peptide | |
PL2714902T3 (pl) | Wektory ekspresyjne do polepszonej sekrecji białka | |
GB201115910D0 (en) | Peptides | |
EP2657337A4 (fr) | Protéine de fusion | |
EP2598636A4 (fr) | Vecteurs et procédés d'expression de protéines recombinantes | |
SG10201507721SA (en) | CHO-GMT Recombinant Protein Expression | |
EP2521787A4 (fr) | Expression de protéine améliorée | |
GB201220899D0 (en) | CD44v6-derived pegylated peptides | |
ZA201207425B (en) | Fusion protein | |
GB201107468D0 (en) | Protein expression systems | |
HK1187628A1 (zh) | 新型肽 | |
EP2771689A4 (fr) | Peptides usp2a et anticorps | |
EP2668276A4 (fr) | Transduction protéique améliorée | |
EP2714717A4 (fr) | Peptides de phoenixin | |
GB201213672D0 (en) | Protein | |
HK1211952A1 (en) | Recombinant protein | |
GB201103169D0 (en) | Protein expression |